SCHEMBL30045356

SCHEMBL30045356

COc1cc(OC)c(Cl)c(-c2cc3cnc(Cl)cc3cn2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.42
RAB9A P51151 7/20 0.42
CASP3 P42574 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
FGFR4 P22455 2/20 0.39
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP17A1 P05093 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
FGFR1 P11362 2/20 0.35
IDO1 P14902 2/20 0.35
TDO2 P48775 2/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
KDM1A O60341 1/20 0.34
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21240499 1.00 NPC1 (0.42) NPC1RAB9ACASP3SENP7FGFR4
SCHEMBL20331871 0.87 NPC1 (0.41) NPC1RAB9ACASP3SENP7FGFR4
SCHEMBL20331059 0.79 FGFR4 (0.47) NPC1RAB9ACASP3SENP7FGFR4
SCHEMBL20331057 0.77 NPC1 (0.69) NPC1RAB9ACASP3SENP7CYP1A2
SCHEMBL20331874 0.74 FGFR4 (0.45) NPC1RAB9ACASP3SENP7FGFR4
SCHEMBL30045304 0.74 FGFR4 (0.45) NPC1RAB9ACASP3SENP7FGFR4
SCHEMBL21240085 0.73 FGFR2 (0.38) FGFR1KDM1A
SCHEMBL29577369 0.73 FGFR2 (0.38) FGFR1KDM1A
SCHEMBL20331877 0.73 FGFR4 (0.41) NPC1RAB9ACASP3SENP7FGFR4
SCHEMBL30046032 0.73 FGFR4 (0.41) NPC1RAB9ACASP3SENP7FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 US disclosed
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 NPC1 4196/4885RAB9A 3592/4885CASP3 2520/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 NPC1 4289/4885RAB9A 3622/4885CASP3 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.